Breaking Barriers in HER2+ Cancers
- PMID: 32857948
- DOI: 10.1016/j.ccell.2020.07.012
Breaking Barriers in HER2+ Cancers
Abstract
Treatment with the immunoconjugate trastuzumab deruxtecan leads to unprecedented improvements in response and overall survival in patients with HER2-positive (HER2+) metastatic gastroesophageal carcinoma (GEA), according to a study published in the New England Journal of Medicine. Until now, no HER2-targeted drugs other than trastuzumab have shown significant benefit in patients with HER2+ GEA.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment on
-
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous